Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial

Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial
复制标题

DOI:
10.1161/circheartfailure.111.964221
复制
发表时间:
2012-03-01
影响因子:
9.7
通讯作者:
Massie, Barry M.
Massie, Barry M.
中科院分区:
医学1区
文献类型:
--
作者:
Rector, Thomas S.;Carson, Peter E.;Massie, Barry M.

文献摘要

被引文献

相似文献

背景-明尼苏达心力衰竭生活问卷(MLHFQ)被用于一项大型、多国、随机、安慰剂对照试验,以测量射血分数正常的心力衰竭(HF-PEF)对患者生活的不良影响和irbesartan.Methods和Results-Patients有症状的HF-PEF患者被随机分配到irbesartan组(每日最多300 mg)或安慰剂组。在基线(n=3605)、第6个月(n=3137)、第14个月(n=2904)和研究结束(中位数,56个月,n=2205)时进行MLHFQ。基线MLHFQ评分为43 +/- 21,表明HF-PEF具有显著的不良反应。估计重测信度为0.80。基线MLHFQ评分与心力衰竭严重程度的其他指标相关,包括症状、充血体征、心脏结构和心力衰竭导致的住院或死亡时间。呼吸急促或疲劳的轻微改善与MLHFQ评分的显著改善相关(-5.9和-5.0,P
Background-The Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used in a large, multinational, randomized, placebo-controlled trial to measure adverse effects of heart failure with preserved ejection fraction (HF-PEF) on patients' lives and the effects of irbesartan.Methods and Results-Patients with symptomatic HF-PEF were randomly assigned to irbesartan (up to 300 mg daily) or placebo. The MLHFQ was administered at baseline (n=3605), month 6 (n=3137), month 14 (n=2904), and the end of study (median, 56 months, n=2205). Baseline MLHFQ scores of 43 +/- 21 indicated that HF-PEF had a substantial adverse effects. Estimated retest reliability was 0.80. Baseline MLHFQ scores were associated with other measures of the severity of heart failure including symptoms, signs of congestion, cardiac structure, and time to hospitalizations or deaths attributed to heart failure. Slight improvement in shortness of breath or fatigue was associated with significant improvement in MLHFQ scores (-5.9 and -5.0, P